BiomX (NYSEAMERICAN:PHGE – Get Free Report) is expected to post its Q1 2025 quarterly earnings results before the market opens on Thursday, May 15th. Analysts expect the company to announce earnings of ($0.42) per share for the quarter.
BiomX Stock Performance
NYSEAMERICAN:PHGE opened at $0.54 on Tuesday. BiomX has a 52-week low of $0.48 and a 52-week high of $4.90. The company has a market cap of $9.73 million, a price-to-earnings ratio of -0.17 and a beta of 1.27. The company’s fifty day moving average is $0.58.
Analysts Set New Price Targets
Separately, HC Wainwright increased their target price on shares of BiomX from $2.00 to $21.00 and gave the stock a “buy” rating in a research note on Tuesday, April 1st.
About BiomX
BiomX Inc, a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC).
Further Reading
- Five stocks we like better than BiomX
- How to Evaluate a Stock Before Buying
- Palantir’s Latest Deal Could Put a Freeze on Its Stock Price
- How to Find Undervalued Stocks
- 4 Automaker Stocks React to Tariffs: Winners and Losers
- Stock Dividend Cuts Happen Are You Ready?
- Here’s Why Call Option Traders Love Dutch Bros Stock
Receive News & Ratings for BiomX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BiomX and related companies with MarketBeat.com's FREE daily email newsletter.
